Brepocitinib Shows Benefit in Cutaneous Sarcoidosis

A phase 2 trial published in JAMA Dermatology found the drug improved skin disease activity compared with placebo.

Updated on Nov. 17, 2026 in Arthritis

Bold flat-color editorial illustration of three unlabeled capsule shapes stacked beside a small cluster of dots, in deep red, cream, and teal, suggesting a drug trial for a skin condition.
A phase 2 trial of 31 adults published November 10 in JAMA Dermatology found brepocitinib, made by Priovant, improved cutaneous sarcoidosis skin disease versus placebo. AI Illustration. Upload story photo >

A multicenter, randomized, placebo-controlled phase 2 trial of 31 adults with cutaneous sarcoidosis, published online November 10 in JAMA Dermatology, found that brepocitinib improved skin disease activity. Priovant, which manufactures brepocitinib, funded the study.

Why it matters

Cutaneous sarcoidosis, an inflammatory skin condition, currently has limited targeted treatment options, and the trial's results add evidence for a possible new therapy. The findings also come with the disclosure that several study authors have ties to biopharmaceutical companies, which readers may weigh alongside the results.

In a randomized phase 2 trial of 31 adults, CSAMI-A scores improved by 22.3 points on 45 mg and 22.2 points on 15 mg, compared with 0.7 points on placebo at week 16. The trial's longer-term outcomes and performance in larger patient groups remain unreported.

The players

Priovant

Priovant is the company that manufactures brepocitinib and funded the study reported in JAMA Dermatology.

JAMA Dermatology

JAMA Dermatology is a peer-reviewed medical journal published by the American Medical Association that carries dermatology research.

The details

Participants were randomly assigned to brepocitinib 45 mg, brepocitinib 15 mg, or placebo once daily. Higher rates of clear or almost clear skin disease and CSAMI-A response were seen with the 45-mg dose than with placebo, and skin-related quality-of-life improvements accompanied the clinical benefit.

Timeline

  1. Nov. 6 to 11, 2026: American College of Rheumatology annual meeting in Orlando, Florida.

  2. Nov. 10, 2026: JAMA Dermatology published the brepocitinib study online to coincide with the meeting.

  3. Week 16: CSAMI-A scores were measured for efficacy outcomes.

Health Landscape

This result extends the brepocitinib development program, which has been studied in other inflammatory conditions, into cutaneous sarcoidosis, a skin-focused indication with few targeted drugs. The findings are an early step, as phase 2 data typically precede larger phase 3 trials that would be needed before any regulatory decision.

For people living with cutaneous sarcoidosis, the trial suggests a possible future oral option that targets skin disease activity, though it is not yet an approved treatment. Patients should discuss current management options with a clinician rather than seek investigational drugs on the basis of this single early study.

The takeaway

Early trial results can be encouraging, but a single phase 2 study with 31 participants is a starting point rather than proof of benefit. Readers should look for larger, longer trials before drawing conclusions about treatment effectiveness.

Further reading

For background on related inflammatory conditions, explore our Arthritis coverage.